SLC5A2 and Prader-Willi syndrome: However, metformin, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors), and glucagon-like peptide-1 receptor agonists (GLP-1RA) are available choices.[6] We present a patient with PWS and diabetes who demonstrated ketonuria after using Canagliflozin.